Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

OC-1012 completes phase I trial

Aug. 13, 2002

Second phase I study of huN901-DM1 under way

Aug. 13, 2002

Cancer targets selected from Exelixis and Bristol-Myers Squibb collaboration

Aug. 13, 2002

First in vitro study of P80DOX-NP completed

Aug. 12, 2002

Targeted Genetics restructures

Aug. 12, 2002

Biomed-101 phase Ib enrollment completed

Aug. 12, 2002

Initial phase I results for Large Scale Biology's personalized NHL vaccines

Aug. 12, 2002

ProlX receives SBIR grant to advance HIF inhibitor cancer therapy

Aug. 12, 2002

The CXCR4-CXCL12/SDF-1 pathway is a possible target for non-Hodgkin's lymphoma therapy

Aug. 12, 2002

Novel HDAC inhibitors identified at Beacon

Aug. 9, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...